Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2020-03-12 Director's Dealing
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific individual (Park Sang-woo, CEO) in NKMAX. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2020-03-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in shareholding, and major contracts (such as stock collateral loans) of the company's largest shareholder and their special related parties. This document type is specifically used for reporting significant ownership stakes and changes therein, which falls under the 'Major Shareholding Notification' category.
2020-02-21 Korean
조회공시요구(풍문또는보도)(전환사채 발행 추진설)
Regulatory Filings Classification · 95% confidence The document is a formal request from a regulatory body (exchange) to the company (NKMAX) to clarify rumors regarding the issuance of convertible bonds. This is a standard regulatory inquiry/announcement process and does not constitute the actual financial report or a final transaction announcement, fitting best under the general regulatory filings category.
2020-02-19 Korean
조회공시요구(풍문또는보도)에대한답변(미확정)
Regulatory Filings Classification · 95% confidence The document is a formal response to a regulatory inquiry (Korea Exchange) regarding market rumors about a convertible bond issuance. It is a standard regulatory disclosure filing in response to a 'request for disclosure' (조회공시요구), which does not fit into specific categories like M&A or capital updates, making 'RNS' (Regulatory Filings) the most appropriate classification.
2020-02-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This is a standard regulatory disclosure for insider trading or changes in share ownership by company directors/executives. According to the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2020-02-14 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, purpose, and registration process for the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into other specific categories like 'Call Transcript' or 'Investor Presentation', it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure of an event.
2020-02-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.